This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Scores highest PAT of Rs. 118 crore in FY25
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
This significant milestone enhances our global regulatory standing
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Subscribe To Our Newsletter & Stay Updated
